Cathy Eng Archives
New treatment option for metastatic colorectal cancer prolongs survival
Jun. 15, 2023—Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.
Eng stresses need for clinical trial support at cancer forum
Mar. 16, 2023—Vanderbilt's Cathy Eng, MD, stressed the need for more patient participation and better funding for clinical trials to improve colorectal cancer treatment and outcomes during the White House Cancer Moonshot Colorectal Cancer Forum.
Eng invited to White House Cancer Moonshot forum
Mar. 2, 2023—Vanderbilt's Cathy Eng, MD, has been invited to participate in the White House Cancer Moonshot Colorectal Cancer Forum.
Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial
Sep. 13, 2022—Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.
Abramson, Eng, Johnson named to new VICC roles
Aug. 18, 2022—Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.
Trial for colorectal cancer drug reaches primary endpoint
Aug. 17, 2022—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.
Comprehensive framework outlined for addressing early-onset colorectal cancer research
Jan. 25, 2022—New research from Vanderbilt sets a comprehensive framework for addressing research challenges and patient needs for people under 50 with colorectal cancer.
Eng named co-chair of NCI clinical trials steering committee
Sep. 23, 2021—Vanderbilt's Cathy Eng, MD, has been elected co-chair of the National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee.
New drug for metastatic colorectal cancer enters phase 3 trial
Nov. 18, 2020—A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
Study shows better option for treatment of inoperable anal cancer
Jun. 24, 2020—People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform
Feb. 5, 2020—Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.
New Physician Spotlight: Cathy Eng
Nov. 1, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, was recruited to VUMC from The University of Texas MD Anderson Cancer Center in Houston.
